UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 937

Sortiert nach

Molecular Pathways: CDK4 Inhibitors for Cancer Therapy

Clinical cancer research, 2014-07, Vol.20 (13), p.3379-3383

DICKSON, Mark A

2014

Volltextzugriff (PDF)

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

Human pathology, 2015-03, Vol.46 (3), p.357-365

2015

Volltextzugriff (PDF)

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Journal of clinical oncology, 2013-06, Vol.31 (16), p.2024-2028

2013

Volltextzugriff (PDF)

ATRX is a regulator of therapy induced senescence in human cells

Nature communications, 2017-08, Vol.8 (1), p.386-16, Article 386

2017

Volltextzugriff (PDF)

Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates

International journal of cancer, 2013-04, Vol.132 (7), p.1711-1717

2013

Volltextzugriff (PDF)

Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival

Cancer research (Chicago, Ill.), 2020-06, Vol.80 (12), p.2461-2471

2020

Volltextzugriff (PDF)

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Nature communications, 2016-08, Vol.7 (1), p.12609-12609, Article 12609

2016

Volltextzugriff (PDF)

Early treatment-related neutropenia predicts response to palbociclib

British journal of cancer, 2020-09, Vol.123 (6), p.912-918

2020

Volltextzugriff (PDF)

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

Oncogene, 2018-09, Vol.37 (37), p.5066-5078

2018

Volltextzugriff (PDF)

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition

Oncotarget, 2015-04, Vol.6 (10), p.8226-8243

2015

Volltextzugriff (PDF)

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

Clinical cancer research, 2012-05, Vol.18 (9), p.2638-2647

2012

Volltextzugriff (PDF)

Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center

Journal for immunotherapy of cancer, 2022-04, Vol.10 (4), p.e004149

2022

Volltextzugriff (PDF)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas

Cancers, 2023-10, Vol.15 (19), p.4871

2023

Volltextzugriff (PDF)

Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot

Cancer medicine (Malden, MA), 2021-07, Vol.10 (13), p.4221-4227

2021

Volltextzugriff (PDF)

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Journal of clinical oncology, 2015-10, Vol.33 (28), p.3193-3198

2015

Volltextzugriff (PDF)

Liposarcoma: Multimodality Management and Future Targeted Therapies

Surgical oncology clinics of North America, 2016-10, Vol.25 (4), p.761-773

2016

Volltextzugriff (PDF)

Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review

JAMA dermatology (Chicago, Ill.), 2019-03, Vol.155 (3), p.361

2019

Volltextzugriff (PDF)

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial

Oncoimmunology, 2018-01, Vol.7 (1), p.e1372081-e1372081

2018

Volltextzugriff (PDF)

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

Journal of clinical oncology, 2019-02, Vol.37 (4), p.286-295

2019

Volltextzugriff (PDF)

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy

Sarcoma, 2018, Vol.2018, p.2068517-9

2018

Volltextzugriff (PDF)

nab -Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Journal of clinical oncology, 2021-11, Vol.39 (33), p.3660-3670

2021

Volltextzugriff (PDF)

Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”

Sarcoma, 2019-09, Vol.2019, p.1-1

2019

Volltextzugriff (PDF)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Sarcoma, 2015, Vol.2015, p.532478-7

2015

Volltextzugriff (PDF)

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors

Clinical cancer research, 2009-12, Vol.15 (23), p.7405-7411

2009

Volltextzugriff (PDF)

Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications

The American journal of surgical pathology, 2015-06, Vol.39 (6), p.813-825

2015

Volltextzugriff (PDF)

1 – 25 von 937

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(832)
Mit Volltextzugriff
(838)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Molecular Pathways: CDK4 Inhibitors for Cancer Therapy

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

ATRX is a regulator of therapy induced senescence in human cells

Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates

Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Early treatment-related neutropenia predicts response to palbociclib

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas

Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Liposarcoma: Multimodality Management and Future Targeted Therapies

Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy

nab -Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors

Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications

Suchergebnisse filtern